CAR-BCMA T cells

GENETIC3 trials

Sponsors

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, First Affiliated Hospital of Zhejiang University, CARsgen Therapeutics Co., Ltd.

Conditions

Multiple MyelomaRefractory or Relapsed Multiple Myeloma

Phase 1

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

First Affiliated Hospital of Zhejiang UniversityRefractory or Relapsed Multiple Myeloma

Start: 2018-03-23End: 2023-06-23Updated: 2020-10-08

Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

Active, not recruitingNCT03975907

CARsgen Therapeutics Co., Ltd.Multiple Myeloma

Start: 2019-06-10End: 2025-12-31Updated: 2024-03-12

Unknown Phase

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

Xinhua Hospital, Shanghai Jiao Tong University School of MedicineRefractory or Relapsed Multiple Myeloma

Start: 2017-10-13End: 2023-07-02Updated: 2020-10-12

Related Papers

Long-term follow-up of zevor-cel in patients with relapsed/refractory multiple myeloma.

2026-01-01

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood2024-11-052 citations

Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Blood2023-11-0222 citations

Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood2022-11-1523 citations

Sustainable Efficacy and Safety Results from Lummicar Study 1: A Phase 1/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Blood2021-11-0521 citations

Integrated Analysis of B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects By High-Risk Factors

Blood2021-11-059 citations

Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma

Blood2020-11-0435 citations

Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Blood2020-11-0410 citations

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Blood2019-11-1340 citations